reports
Genelux Corporation Reports Second Quarter 2025 Financial Results and ...
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. G...
Genelux Corporation Announces Appointment of Eric Groen as General Cou...
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team,” said Thomas Zindrick, President, CEO, and Chairman of the Board. “Eric brings a power...
The Lovesac Company issues Notice of Settlement of Shareholder Derivat...
The Lovesac Company issues Notice of Settlement of Shareholder Derivative Actions STAMFORD, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today released the following notice: A Federal Court authorized this Notice. This is not a solicitation from a lawyer. TO:ALL PERSONS OR ENTITIES WHO HOLD OR BENEFICIALLY OWN COMMON STOCK OF THE LOVESAC COMPANY AS OF MAY 19, 2025 (“SECURITIES HOLDERS”). PLEASE READ THIS NOTICE CAREFULLY AND COMPLETELY BECAUSE YOUR RIGHTS MIGHT BE AFFECTED BY T...
The Lovesac Company Reports First Quarter Fiscal 2026 Financial Result...
The Lovesac Company Reports First Quarter Fiscal 2026 Financial Results Q1 FY26 Net Sales Increased 4.3% to $138.4 Million vs. Q1 FY25 STAMFORD, Conn., June 12, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the first quarter of fiscal 2026, which ended May 4, 2025. Shawn Nelson, Chief Executive Officer, stated, “Our first quarter performance was inline with our expectations to capitalize on sec...
The Lovesac Company Announces First Quarter Conference Call Date
The Lovesac Company Announces First Quarter Conference Call Date STAMFORD, Conn., May 29, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its first quarter financial results will be released before market open on Thursday, June 12, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-493-678...
Genelux Corporation Reports First Quarter 2025 Financial Results and P...
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates. “The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase ...
Genelux Corporation to Participate in a Fireside Chat at the Citizens ...
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board, and , CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursd...
The Lovesac Company Appoints Heidi Cooley as Chief Brand and Marketing...
The Lovesac Company Appoints Heidi Cooley as Chief Brand and Marketing Officer Seasoned Executive and Proven Brand Strategist to Accelerate the Company’s Next Chapter of Growth STAMFORD, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced the appointment of Heidi Cooley as Chief Brand and Marketing Officer, effective April 23, 2025. Ms. Cooley will be the first Chief Brand and Marketing Officer for Lovesac and will lead all aspects of marketing, eCommerce and brand str...
The Lovesac Company Reports Fourth Quarter And Fiscal 2025 Financial R...
The Lovesac Company Reports Fourth Quarter And Fiscal 2025 Financial Results Fourth Quarter Net Sales of $241.5 million Fiscal Year Net Sales of $680.6 million STAMFORD, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the fourth quarter and full year fiscal 2025, which ended February 2, 2025. Note: Lovesac's prior year fourth quarter and fiscal 2024 results contain an additional,...
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financia...
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif....
The Lovesac Company Announces Fourth Quarter and Fiscal 2025 Conferenc...
The Lovesac Company Announces Fourth Quarter and Fiscal 2025 Conference Call Date STAMFORD, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its fourth quarter and fiscal 2025 financial results will be released before market open on Thursday, April 10, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (internatio...
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Of...
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners G...
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of ...
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. – Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ra...
Genelux Announces Alignment with FDA on Key Elements of the Approval P...
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease - U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant/r...
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation Announces New Chief Financial Officer WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt’s financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux,” said Thomas Zindrick, President, CEO and Chairman of the Board. “His unique combination of financial expertis...
- Jonathan Moreland
OMEX ODYSSEY MARINE EXPLORATION INC.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
LOVE INC.
FUND EARTH SCIENCE TECH
ANIX LOVESAC
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NOTV DELCATH SYSTEMS
NVCT EATON VANCE NEW YORK MUNICIPAL BOND FUND
ANEB PRELUDE THERAPEUTICS
BHVN INOTIV
ACXP INC.
BUKS NUVECTIS PHARMA INC
GLSI ANEBULO PHARMACEUTICALS INC
MEGI BIOHAVEN LTD
CVI ACURX PHARMACEUTICALS INC
SRFM BUTLER NATIONAL CORP
OCX GREENWICH LIFESCIENCES INC
AVDL MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
TXO CVR ENERGY
MRKR INC.
TTGT SURF AIR MOBILITY INC.
DTIL ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM MORNINGSTAR PARTNERS
IBIO L.P.
SDHY MARKER THERAPEUTICS INC
TECHTARGET INC.
PRECISION BIOSCIENCES INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
VRSN VERISIGN INC.
OMEX ODYSSEY MARINE EXPLORATION INC.
LNDC LANDEC CORP.
FPI FARMLAND PARTNERS REIT
DEA EASTERLY GOVERNMENT PROPERTIES INC
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ZIVO ZIVO BIOSCIENCE
LOVE INC.
FUND LOVESAC
ETON ROYCE FOCUS TRUST
MCFT INC.
PGNY ETON PHARMACEUTICALS
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
REYN DELCATH SYSTEMS
PRLD EATON VANCE NEW YORK MUNICIPAL BOND FUND
NOTV REYNOLDS CONSUMER PRODUCTS INC.
PFX PRELUDE THERAPEUTICS
XLO INOTIV
NVCT INC.
ANEB PHENIXFIN CORP
BHVN XILIO THERAPEUTICS INC
ACXP NUVECTIS PHARMA INC
BUKS ANEBULO PHARMACEUTICALS INC
ECBK BIOHAVEN LTD
GLSI ACURX PHARMACEUTICALS INC
MEGI BUTLER NATIONAL CORP
SCWO ECB BANCORP INC.
CVI GREENWICH LIFESCIENCES INC
SRFM MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
OCX 374WATER INC
SIRI CVR ENERGY
TXO INC.
MRKR SURF AIR MOBILITY INC.
TTGT ONCOCYTE CORPORATION
DTIL SIRIUS XM HLDGS INC NEW
AMST MORNINGSTAR PARTNERS
WHLM L.P.
MARKER THERAPEUTICS INC
TECHTARGET INC.
PRECISION BIOSCIENCES INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
The Lovesac Company Announces Participation in the 2025 ICR Conference
The Lovesac Company Announces Participation in the 2025 ICR Conference STAMFORD, Conn., Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, today announced that the Company is scheduled to participate in the 2025 ICR Conference on Tuesday, January 14, 2025, at 11:00 a.m. Eastern Time. The fireside chat will be webcast live over the Internet and can be accessed on the Company’s Investor Relations website, investor.lovesac.com. An online archive will be ...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
VVI VIAD CORP
VRSN VERISIGN INC.
OMEX ODYSSEY MARINE EXPLORATION INC.
MMS MAXIMUS INC.
KVHI KVH INDUSTRIES INC.
FPI FARMLAND PARTNERS REIT
FDX FEDEX CORPORATION
DEA EASTERLY GOVERNMENT PROPERTIES INC
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
PLSE PULSE BIOSCIENCES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
ZIVO ZIVO BIOSCIENCE
WHLM INC.
LOVE WILHELMINA INTERNATIONAL
FUND LOVESAC
MCFT ROYCE FOCUS TRUST
PGNY INC.
OXLC MASTERCRAFT BOAT HOLDINGS
ZYME PROGYNY
DCTH OXFORD LANE CAPITAL CORP.
REYN ZYMEWORKS INC.
PRLD DELCATH SYSTEMS
DLHC REYNOLDS CONSUMER PRODUCTS INC.
MASS PRELUDE THERAPEUTICS
NOTV DALEIGH HOLDINGS CORP
PFX 908 DEVICES
XLO INOTIV
NVCT INC.
ANEB PHENIXFIN CORP
BHVN XILIO THERAPEUTICS INC
BUKS NUVECTIS PHARMA INC
ECBK ANEBULO PHARMACEUTICALS INC
GLSI BIOHAVEN LTD
MEGI BUTLER NATIONAL CORP
SCWO ECB BANCORP INC.
SRFM GREENWICH LIFESCIENCES INC
OCX MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
SUNS 374WATER INC
SIRI SURF AIR MOBILITY INC.
TXO ONCOCYTE CORPORATION
MRKR SUNRISE REALTY TRUST
TTGT SIRIUS XM HLDGS INC NEW
KALA MORNINGSTAR PARTNERS
DTIL L.P.
MARKER THERAPEUTICS INC
TECHTARGET INC.
KALA BIO INC
PRECISION BIOSCIENCES INC.
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
OMEX ODYSSEY MARINE EXPLORATION INC.
GLP GLOBAL PARTNERS LP
FDX FEDEX CORPORATION
DEA EASTERLY GOVERNMENT PROPERTIES INC
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
AGR AVANGRID INC.
LW LAMB WESTON HOLDINGS INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
LILA LIBERTY LATIN AMERICA A
LOVE LOVESAC
PGNY PROGYNY
ZYME ZYMEWORKS INC.
DCTH DELCATH SYSTEMS
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
PRLD PRELUDE THERAPEUTICS
UAN CVR PARTNERS LP
NOTV INOTIV
RMBL INC.
VTYX RUMBLEON INC
QNRX VENTYX BIOSCIENCES INC
ANEB QUOIN PHARMACEUTICALS LTD
TCBX ANEBULO PHARMACEUTICALS INC
BIGZ THIRD COAST BANCSHARES INC
SKYH BLACKROCK INNOVATION AND GROWTH TST
SRFM SKY HARBOUR GROUP CORP
OCX SURF AIR MOBILITY INC.
MIO ONCOCYTE CORPORATION
SUNS PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
ASMB SUNRISE REALTY TRUST
BNTC ASSEMBLY BIOSCIENCES INC
EVM BENITEC BIOPHARMA INC
MRKR EATON VANCE INSD CALIF MUN BD FD
TTGT MARKER THERAPEUTICS INC
TECHTARGET INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.